IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab

ABSTRACT:

Background

Prognostic factors for initial response of advanced cutaneous squamous cell carcinoma to cemiplimab treatment are lacking. Il-6 has been found to affect immune cell populations which impact tumor development. The aim was to investigate the prognostic significance of IL-6 serum levels before and during treatment.

Methods

Serum levels of IL-6 were correlated with clinical outcomes in a retrospective study.

Results

Overall, 39 patients were enrolled. High serum levels of IL-6 (> 5.6 pg/ml) were associated with poorer survival (45.1% vs 0 deaths; OS: 16.1 ± 1.5 vs 20.8 ± 0 months, 95% CI 13,046 to 19,184) and shorter PFS (10.3 ± 1.9 vs 18.9 ± 1.5 months; 95% CI 3433 to 10,133) in patients with advanced CSCC treated with cemiplimab. In addition, patients wh

SUBMITTER: Mallardo D 

PROVIDER: S-EPMC9948392 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature